Agalsidase beta Completed Phase 4 Trials for Fabry's Disease Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT01650779A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta
NCT01997489Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients.
NCT00074984A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease
NCT00081497A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease
NCT00097890Replagal Enzyme Replacement Therapy for Adults With Fabry Disease
NCT00140621A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease